Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

Journal of Clinical Oncology

Volumn 19, Issue 15, 2001, Pages 3483-3489

  Patel, S R ^a   Gandhi, V ^a   Jenkins, J ^a   Papadopolous, N ^a   Burgess, M A ^a   Plager, C ^a   Plunkett, W ^a   Benjamin, R S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; GEMCITABINE TRIPHOSPHATE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; LEG EDEMA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MYALGIA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOFT TISSUE SARCOMA; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0035424877     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.15.3483     Document Type: Article

References (25)

1. Cancer Statistics
2. Evaluation of ifosfamide in metastatic leiomyosarcomas of GI origin
3. Differential Responsiveness of leiomyosarcoma (leio) arising at different sites to doxorubicin-based chemotherapy
4. Dose-intensive chemotherapy for soft-tissue sarcomas
5. New agents in the treatment of soft-tissue sarcomas
6. State of the art treatment of solid tumors with Gemcitabine
7. Gemcitabine: Current status of phase I and II trials
8. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of Gemcitabine
9. Gemcitabine (2′,2′-difluorodeoxycytidine) in leukemia: A phase I clinical, plasma and cellular pharmacology study
10. A phase 1 trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic, cancer and other solid tumors
11. Clinical results of a pharmacodynamically based strategy for higher dosing of gemcitabine in patients with solid tumors
12. Quantitation of 1-b-D-arabinofuranosylcytosine 5′- triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-b-D-arabinofuranosylcytosine therapy
13. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides
14. Optimal two-stage designs for phase II clinical trials
15. A phase I clinical, plasma and cellular pharmacology study of gemcitabine
16. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation
17. Limited activity and acceptable toxicity of gemcitabine in a phase 2 study of patients with advanced sarcomas: A Mayo Cancer Center Study
18. Gemcitabine in soft-tissue or bone sarcoma resistant to standard chemotherapy: A phase 2 study
19. Phase II trial of gemcitabine in patients with pretreated advanced soft-tissue sarcomas
20. Nucleotide specificity of human deoxycytidine kinase
21. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma
22. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxcytidine
23. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells
24. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis
25. Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair